Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,101 to 4,120 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Intervention - Nocturnal Coverage vs Control - Standard of Care: Discharge Home From Hospital | 317 of 820 314 of 778 | -1.7 points -6.5 to 3.1 | 1,598 | NCT01434823 24 Hour Intensivist Coverage in the Medical Intensive Care Unit |
| Intervention - Nocturnal Coverage vs Control - Standard of Care: Re-admission to the MICU Within 48 Hours | 32 of 820 21 of 778 | 1.2 points -0.6 to 3.0 | 1,598 | NCT01434823 24 Hour Intensivist Coverage in the Medical Intensive Care Unit |
| Intervention - Nocturnal Coverage vs Control - Standard of Care: In-hospital Mortality | 203 of 820 177 of 778 | 2.0 points -2.2 to 6.2 | 1,598 | NCT01434823 24 Hour Intensivist Coverage in the Medical Intensive Care Unit |
| Dabigatran 220mg vs Enoxaparin: Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period | 17 of 804 31 of 793 | -1.8 points -3.6 to -0.1 | 1,597 | NCT00657150 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty |
| Intervention Arm vs Usual Care: deaths from any cause | 142 of 754 130 of 842 | 3.4 points -0.3 to 7.1 | 1,596 | NCT03832595 Kidney Coordinated Health Management Partnership |
| Intervention Arm vs Usual Care: serious adverse events | 18 of 754 21 of 842 | -0.1 points -1.7 to 1.5 | 1,596 | NCT03832595 Kidney Coordinated Health Management Partnership |
| Indacaterol 150 μg vs Tiotropium 18 μg: serious adverse events | 22 of 794 30 of 799 | -1.0 points -2.8 to 0.8 | 1,593 | NCT00900731 A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) |
| PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: Mortality | 24 of 486 23 of 1,106 | 2.9 points 1.0 to 5.3 | 1,592 | NCT05481216 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV |
| PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: deaths from any cause | 24 of 486 23 of 1,106 | 2.9 points 1.0 to 5.3 | 1,592 | NCT05481216 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV |
| PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: Number of Palliative Discharge | 1 of 486 0 of 1,106 | 0.2 points -0.2 to 1.2 | 1,592 | NCT05481216 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV |
| PLWHIV With COVID-19 Cases vs HIV Seronegative Patients With COVID-19 Controls: serious adverse events | 224 of 486 231 of 1,106 | 25.2 points 20.2 to 30.2 | 1,592 | NCT05481216 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV |
| Arm A - Ivermectin 400 vs Arm A - Placebo: Number of Participants With Mortality | 1 of 817 0 of 774 | 0.1 points -0.4 to 0.7 | 1,591 | NCT05736861 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) |
| Arm A - Ivermectin 400 vs Arm A - Placebo: Number of Participants With Hospitalization or Death | 10 of 817 9 of 774 | 0.1 points -1.1 to 1.2 | 1,591 | NCT05736861 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) |
| Arm A - Ivermectin 400 vs Arm A - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death | 32 of 817 28 of 774 | 0.3 points -1.6 to 2.2 | 1,591 | NCT05736861 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) |
| Arm A - Ivermectin 400 vs Arm A - Placebo: deaths from any cause | 1 of 817 0 of 774 | 0.1 points -0.4 to 0.7 | 1,591 | NCT05736861 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) |
| Arm A - Ivermectin 400 vs Arm A - Placebo: serious adverse events | 13 of 817 17 of 774 | -0.6 points -2.1 to 0.8 | 1,591 | NCT05736861 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) |
| Toremifene 20mg vs Placebo: serious adverse events | 117 of 787 137 of 802 | -2.2 points -5.8 to 1.4 | 1,589 | NCT00106691 Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) |
| Feedback On vs Feedback Off: Survival to Hospital Discharge | 92 of 815 96 of 771 | -1.2 points -4.4 to 2.0 | 1,586 | NCT00539539 Automated Real-time Feedback on CPR Study |
| Feedback On vs Feedback Off: Rate of ROSC During the Prehospital Resuscitation | 361 of 815 345 of 771 | -0.5 points -5.3 to 4.4 | 1,586 | NCT00539539 Automated Real-time Feedback on CPR Study |
| Feedback On vs Feedback Off: Pulses Present at ED Arrival. | 260 of 815 243 of 771 | 0.4 points -4.2 to 5.0 | 1,586 | NCT00539539 Automated Real-time Feedback on CPR Study |
Code
curl "https://conductscience.org/api/comparisons/v1?page=206"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=206
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01434823-309f0247",
"title": "Intervention - Nocturnal Coverage vs Control - Standard of Care: Discharge Home From Hospital",
"summary": "317 of 820 against 314 of 778; risk difference -1.7 points, 95% interval -6.5 to 3.1; NCT01434823, 24 Hour Intensivist Coverage in the Medical Intensive Care Unit",
"record": "/library/comparisons/NCT01434823-309f0247",
"nct_id": "NCT01434823",
"kind": "outcome",
"participants": 1598,
"risk_difference": {
"value": -0.017013605868706483,
"lower": -0.06483439683852027,
"upper": 0.030861397733051438
},
"group_1": "317 of 820",
"group_2": "314 of 778",
"difference": "-1.7 points",
"interval": "-6.5 to 3.1",
"trial_title": "24 Hour Intensivist Coverage in the Medical Intensive Care Unit"
},
{
"id": "NCT01434823-48da2287",
"title": "Intervention - Nocturnal Coverage vs Control - Standard of Care: Re-admission to the MICU Within 48 Hours",
"summary": "32 of 820 against 21 of 778; risk difference 1.2 points, 95% interval -0.6 to 3.0; NCT01434823, 24 Hour Intensivist Coverage in the Medical Intensive Care Unit",
"record": "/library/comparisons/NCT01434823-48da2287",
"nct_id": "NCT01434823",
"kind": "outcome",
"participants": 1598,
"risk_difference": {
"value": 0.01203210232616465,
"lower": -0.005863454730615884,
"upper": 0.030133169098504282
},
"group_1": "32 of 820",
"group_2": "21 of 778",
"difference": "1.2 points",
"interval": "-0.6 to 3.0",
"trial_title": "24 Hour Intensivist Coverage in the Medical Intensive Care Unit"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=207",
"request_id": "PHZXO20_zQar1RMl"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant